2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Molecular Testing, Clinical Procedures, Treatment Considerations, Combination Therapy, Supportive Care, Biological Therapies, Non-Biological Therapies, Chemotherapy, Adverse Events, Artificial Intelligence (AI), Machine Learning, Biological Processes, Immune Mechanism, Molecular Biology, Clinical Practice (Health Services and Quality), Patient Safety, Practice Models, Value, Diseases, Bleeding and Clotting, Immunology, Infectious Diseases, Fungal, Lymphoid Malignancies, Lymphoid Leukemias, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, ALL, Research, AML, Translational Research, MDS, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly, Pediatric, Young Adult
PAPER

1587 Association between time to treatment initiation and survival in IDH1-mutated AML: a retrospective, multinational database study (REAL-IDH)

Joshua F. Zeidner, MD, Christian Recher, MD, PhD2, Vanessa Lacoste3, Annett Kucka4, Anne-Marie De La Bigne, PhD5, Pierre-Yves Dumas, MD, PhD6
1 University of North Carolina, Chapel Hill, North Carolina, United States
2 Université de Toulouse, CHU de Toulouse, Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse, France
3 Servier Medical Affairs, Suresnes, France
4 Servier, Munich, Germany
5 Servier Medical Affairs, Suresnes, France
6 CHU Bordeaux, Bordeaux, France

Background: Acute myeloid leukemia (AML) is an aggressive and molecularly heterogeneous malignancy, traditionally treated as a clinical emergency. With the advent of targeted therapies, evolving treatment landscape, and the advances in prognostic risk stratification, molecular testing has become increasingly important for optimal care. Recent retrospective analyses have suggested that treatment can be safely deferred while awaiting molecular results in adults with AML across a broad age range (Röllig et al., 2020; Baden et al., 2024). However, it remains unclear whether these findings apply to patients with targetable mutations such as IDH1. The REAL‑IDH real-world (RW) evidence study is evaluating the clinical and molecular landscape of AML and its impact on patient management. Here, we assess the association between time from AML diagnosis to treatment initiation and survival outcomes in patients with IDH1-mutated (IDH1m) AML.

Methods: This was a retrospective, longitudinal, observational cohort study conducted using RW databases from France (FR) (DATAML registry) and the USA (Cancer Outcomes Tracking and Analysis [COTA]). The study used data from January 1, 2017, through December 31, 2024, for DATAML, and through November 15, 2024, for COTA. Patients were followed up from the first AML diagnosis date to date of loss to follow-up, death, or study end, whichever occurred first. Eligible patients aged ≥18 years had a first record of AML diagnosis within the index period (January 1, 2017, to 18 months and 12 months prior to the data cut-off for intensive chemotherapy [IC]-treated and non-IC-treated patients, respectively). In COTA, patients were required to have a record of IDH1m present within 30 days prior to the first AML diagnosis date or up to 90 days after initiation of first-line therapy, and at least one record of systemic anti-cancer therapy (SACT) (≤30 days before, on, or at any time after the first AML diagnosis date). In DATAML, patients only required a recorded IDH1 test result, with no date restriction on IDH1 testing or SACT relative to first AML diagnosis date. Overall survival (OS) was assessed according to time from AML diagnosis to the start of first-line therapy (i.e., from Day 7). A landmark analysis was performed on patients alive on Day 7 after diagnosis, for whom an early crude (n/N proportions) mortality rate was obtained (30 and 60 days after Day 7, respectively); data were assessed in patients with IDH1m AML (pooled IC-treated and non-IC-treated patients) grouped relative to the day of diagnosis and treatment initiation. Selected DATAML data were masked to prevent calculation of low-frequency values in accordance with data disclosure requirements. No formal statistical assessment was performed for comparisons between subgroups.

Results: Overall, 1,142 and 980 patients from FR and the USA, respectively, were tested for IDH1, of whom 10.2% (116/1,142) and 10.5% (103/980) had IDH1m AML. Of 116 FR patients with IDH1m AML, 29.3% (34/116) and 70.7% (82/116) started treatment at Day ≤7 and Day >7 from diagnosis, respectively. Of 103 USA patients with IDH1m AML, 53.4% (55/103) and 46.6% (48/103) started treatment at Day ≤7 and Day >7 from diagnosis, respectively. Median OS of Day ≤7 and Day >7 treatment-initiation subgroups for the IDH1m AML FR group was 20.6 months (8.4–not reached [NR]) vs 16.6 months (10.7–23.2). For the IDH1m AML USA group, median OS was 34.6 months (19.7–NR) vs 27.0 months (18.4–50.1). In the IDH1m AML FR population, crude mortality rates for Day ≤7 and Day >7 treatment-initiation subgroups were ≤29.4% vs ≤12.2% at both 30 and 60 days. In the IDH1m USA population, crude mortality rates for Day ≤7 and Day >7 were 1.8% vs 4.2% at 30 days, and 5.5% vs 12.5% at 60 days, respectively.

Conclusion: In this exploratory observational analysis, OS and mortality rates were similar between patients who initiated treatment rapidly within 7 days and those who deferred treatment for >7 days in newly diagnosed IDH1m AML. In the era of precision medicine-based treatment approaches, these findings support the recommendation to defer treatment initiation until a full genomic profile has been obtained in newly diagnosed patients with AML. 

Joshua F. Zeidner, MD: Sumitomo Dainippon Pharma - Research Funding; Novartis - Research Funding; Zentalis Pharmaceuticals - Research Funding; Akesobio - Research Funding; Ascentage - Research Funding; Shattuck Labs - Research Funding; Faron - Research Funding; SELLAS Life Sciences - Research Funding; Innocare - Research Funding; Lin Biosciences - Research Funding; Stemline - Research Funding; Arog Pharmaceuticals - Research Funding; Jazz Pharmaceuticals - Research Funding; Aptevo Therapeutics - Research Funding; Auron Therapeutics - Research Funding; AstraZeneca - Research Funding; Daiichi Sankyo - Research Funding; Geron - Consultancy (Includes expert testimony); Johnson & Johnson - Consultancy (Includes expert testimony); Ascentage - Consultancy (Includes expert testimony); AstraZeneca - Consultancy (Includes expert testimony); Shattuck Labs - Consultancy (Includes expert testimony); Servier - Consultancy (Includes expert testimony); NeoGenomics - Consultancy (Includes expert testimony); Sumitomo Dainippon Pharma - Consultancy (Includes expert testimony); Foghorn - Consultancy (Includes expert testimony); Halia Therapeutics - Consultancy (Includes expert testimony); Relmada Therapeutics - Consultancy (Includes expert testimony); SELLAS Life Sciences - Consultancy (Includes expert testimony); AbbVie - Consultancy (Includes expert testimony); Syndax - Consultancy (Includes expert testimony); Cullinan Therapeutics - Consultancy (Includes expert testimony); Ipsen - Consultancy (Includes expert testimony); Daiichi Sankyo - Consultancy (Includes expert testimony); Genentech - Consultancy (Includes expert testimony); Crossbow Therapeutics - Consultancy (Includes expert testimony); Novartis - Consultancy (Includes expert testimony); Kura Oncology - Consultancy (Includes expert testimony); Aveo Pharmaceuticals - Consultancy (Includes expert testimony); Jazz Pharmaceuticals - Consultancy (Includes expert testimony); Genmab - Consultancy (Includes expert testimony); Astellas - Consultancy (Includes expert testimony); Rigel - Consultancy (Includes expert testimony)